You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》摩通予百濟神州(06160.HK)「增持」評級 下調目標價至222元
阿思達克 01-13 10:30
摩根大通發表研究報告,予百濟神州(06160.HK)H股「增持」評級,目標價由240元降至222港元,此按現金流折現率作估值。 該行稱,公司是商業化階段生物醫藥企業,具經驗證能力開發及商業化創新藥以應對中國及全球病人尚未被滿足的需要。自2010年開業以來,公司發展成全面整合的生物藥企,具強力醫藥發現引擎,同類最優(BIC)臨床營運及具經營往績,屬內地最大型腫瘤藥商業化平台之一,並具昂貴的生產設備。依賴豐富的產品線,全面整合平台,以及遍布全球的生意網絡,料百濟神州可捕捉全球增長機遇,及料迎來多項催化劑刺激股價上行。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account